Loading
This study tests a PARP inhibitor; the registry reports that it is active not recruiting.
The registry lists NCT04915755 as active not recruiting, last updated 2025-07-16. Enrolment is 40 actual participants. Interventions: Niraparib, Placebo. Primary measures include Number of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs); Number of Participants With TEAEs Leading to Death. Results are posted in the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
40 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2025-07-16), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With TEAEs Leading to Deathprimary | Niraparib | 18 | 0 participants | - | - | link |
| Placebo | 22 | 0 participants |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Niraparib, GSK, PARP inhibitors and the tag pipeline.
Shares Niraparib, GSK, PARP inhibitors and the tag pipeline.
Shares Niraparib, GSK, PARP inhibitors and the tag pipeline.
Shares Niraparib, PARP inhibitors and the tag pipeline.
Shares Niraparib, PARP inhibitors and the tag pipeline.
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Early triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/